Genmab A/SvsEli Lilly and Company

GMAB and LLY stock compared: price, dividend, valuation and results, from SEC filings.

LLY

Eli Lilly and Company

$1,347.11

Value $1.27T

-0.30%
LLY's page

Genmab A/S (GMAB) has a market value of $32.5B and Eli Lilly and Company (LLY) $1.27T. Over the last year, with dividends, GMAB moved +65.5% and LLY +29.1%. The P/E is 33.8 for GMAB and 46.1 for LLY. Dividend yield: GMAB none, LLY 0.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    GMAB$32.5B

    LLY$1.27T

    LLY is 39 times GMAB

  • Revenue, 12 months

    GMAB$3.7B

    LLY$86.5B

    LLY is 23 times GMAB

  • Net income, 12 months

    GMAB$963M

    LLY$27.6B

    LLY is 29 times GMAB

  • Operating margin

    GMAB28.6%

    LLY–

  • ROIC

    GMAB7.8%

    LLY35.5%

    27.7 points apart

  • P/E

    GMAB33.8

    LLY46.1

    LLY is 1.4 times GMAB

  • Dividend yield

    GMAB0.0%

    LLY0.5%

    0.5 points apart

  • 5-year return

    GMAB+22.0%

    LLY+439.5%

    417.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

GMAB+22.0%

LLY+439.5%

20040060020222023202420252026
Returns by period
PeriodGMABWith dividendsLLYWith dividends
1 year since November 19, 2025+65.5%Price +65.5%+29.1%Price +28.3%
3 years since November 20, 2023+55.9%+15.9% a yearPrice +55.9%+130.0%+32.0% a yearPrice +125.4%
5 years since November 19, 2021+22.0%+4.1% a yearPrice +22.0%+439.5%+40.1% a yearPrice +416.7%
10 years since November 21, 2016+177.1%+10.7% a yearPrice +177.1%+1,944.6%+35.2% a yearPrice +1,657.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

GMABGenmab A/SLLYEli Lilly and Company

Valuation

GMABLLY
Valuation
Price$50.60$1,347.11
Market value$32.5B$1.27T
Enterprise value (EV)$35.9B$1.32T
P/E33.846.1
P/E, 5-year median4.849.9
P/B5.631.6
EV/EBIT33.837.8
Free cash flow yield3.5%1.6%

Results and growth

GMABLLY
Results and growth
Revenue, 12 months$3.7B$86.5B
Net income, 12 months$963M$27.6B
Free cash flow, 12 months$1.1B$19.7B
Earnings per share, 12 months$1.54$30.81
Revenue growth, year on year19.2%44.7%
Revenue growth a year, past+24.8%over 2 years+21.6%over 5 years
EPS growth a year, past-51.7%over 2 years+27.6%over 5 years

Margins and returns on capital

GMABLLY
Margins and returns on capital
Gross margin93.6%83.6%
Operating margin28.6%–
Net margin25.9%31.9%
ROIC7.8%35.5%
ROE16.5%88.6%

Balance sheet

GMABLLY
Balance sheet
Cash$1.7B$4.9B
Total debt$5.2B$49.5B
Net debt / EBITDA–1.2
Interest cover4.0×38.9×

Dividends and buybacks

GMABLLY
Dividends and buybacks
Dividend yield–0.5%
Dividend per share, 12 months–$6.34
Dividend growth a year, past–+15.2%over 5 years
Buyback yield1.3%0.3%
Shareholder yield1.3%0.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: GMAB or LLY

Didn't find what you were looking for?

Ask us
Which is bigger, Genmab A/S or Eli Lilly and Company?

By market value, Eli Lilly and Company ($1.27T) is about 39.1 times Genmab A/S ($32.5B), at today's prices.

How did GMAB and LLY stock do over the last 10 years?

Since November 21, 2016, GMAB's price moved +177.1% and LLY's +1,657.7%. With dividends: GMAB +177.1% (+10.7% a year), LLY +1,944.6% (+35.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, GMAB or LLY?

The dividend yield at today's price is none for Genmab A/S and 0.47% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.

What is the P/E of GMAB and LLY?

At today's price, the P/E is 33.8 for GMAB and 46.1 for LLY. The median of the last five years was 4.8 and 49.9, which shows where each stands against its own past.

Which has the higher profit margins, Genmab A/S or Eli Lilly and Company?

Over the last twelve months, the net margin was 25.9% for Genmab A/S and 31.9% for Eli Lilly and Company, and the operating margin 28.6% and –. Revenue was $3.7B and $86.5B.

Which is the better investment, Genmab A/S or Eli Lilly and Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.